In humans, andrographolide was detected to inhibit NF-κB activation induced by COX-2 by targeting p300 for breast cancer treatment; it was also reported to suppress VEGF-derived endothelial cell motility by impairing cofilin activity and the formation of stress fiber, thus suppressing breast cancer angiogenesis [217]. Here, VEGFA is linked to breast carcinoma.